



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20852

RECEIVED
JAN 2000
Re: Requip®
Docket No. 98E-0478
OFFICE OF THE ASSISTANT
COMMISSIONER FOR PATENTS

DEC 28 1999

The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for
Patent Policy and Projects
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the patent term extension application for U.S. Patent No. 4,452,808 filed by SmithKline Beecham Corp. under 35 U.S.C. § 156. The patent claims the human drug product Requip® (ropinirole), new drug application NDA 20-658.

In the December 21, 1998, issue of the Federal Register (63 Fed. Reg. 70411), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before June 21, 1999, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Stephen Venetianer
SmithKline Beecham Corp
Corp. Intellectual Property UW2220
P.O. Box 1539, 709 Swedeland Road
King of Prussia, PA 19406-0939

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service


Food and Drug Administration

Rockville MD 20857

HFD-7

Official Business

Penalty For Private Use \$300



The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for Patent
Policy and Projects
Office of the Assistant Commissioner for
Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

RECEIVED

JAN 11 2000

PTO MAIL CENTER